Acadia Pharmaceuticals | ACAD - 资产



金融业
股票价格
USD
资产
USD 1.74B
现金及等价物
USD 956.47M
销售成本
USD 28.32M
流动资产
USD 1.22B
流动负债
USD 361.44M
债务
USD 50.79M
EBIT
USD 37.84M
EBITDA
USD -1.62M
员工
653
EPS每股收益
USD 0.18
股本和储备
USD 1.31B
销售毛利
USD 279.64M
债务利息支出
USD 0
利息收入
USD 8.06M
贷款资金
USD 0
市值
USD 4.86B
净收入
USD 31.5M
营业费用
USD 270.12M
营业利润
USD 37.84M
普通股股本
USD 171.09M
PE价格收益
11.33
税前利润
USD 46.47M
销售收入
USD 307.96M
销售和管理费用
USD 148.57M
股票
USD 108.67M
贸易债权人
USD 44.57M
应收帐款人
USD 166.33M


资产 更改 日
Acadia Pharmaceuticals USD 1.74B 137.67M 2026-06
ALKERMES USD 4.39B 135.05M 2026-06
Alnylam Pharmaceuticals USD 5.56B 429.22M 2026-06
Biogen USD 32.09B 2.6B 2026-06
BioMarin Pharmaceutical USD 11.72B 3.13B 2026-06
Bristol-Myers Squibb USD 87.63B 1.16B 2026-06
Cara Therapeutics USD 25.82M 6.26M 2026-03
Corcept Therapeutics USD 888.7M 73.82M 2026-06
Cytokinetics USD 1.92B 651.07M 2026-06
Eisai JPY 1.56T 108.98B 2026-06
Eli Lilly USD 142.28B 25.71B 2026-06
Incyte USD 7.87B 533.53M 2026-06
J&J USD 201.06B 167M 2026-06
Moderna USD 10.96B 527M 2026-06
Neurocrine Biosciences USD 5.36B 452.9M 2026-06
Pfizer USD 201.13B 6.49B 2026-06
Prothena USD 302.58M 47.32M 2026-06
PTC Therapeutics USD 3.25B 381.37M 2026-06
Sarepta Therapeutics USD 3.19B 9.58M 2026-06
Ultragenyx Pharmaceutical USD 1.26B 32M 2026-06
Vanda Pharmaceuticals USD 488.95M 112.19M 2025-12
Vertex Pharmaceuticals USD 27.42B 938.9M 2026-06